Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Heatmap
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
X
XBI
State Street SPDR S&P Biotech ETF
136.2
0
USD
+9917.65%
Sektor:
Finanzen
Basis:
USD
Gewinnwährung:
USD
Tagesspanne
Jahresspanne
Tagesänderung
+9917.65%
Monatliche Änderung
+5.17%
6 month change
+11.88%
Jahresänderung
+23.67%
Vorheriger Schlusskurs
1.3
6
Open
136.4
8
Tief
136.1
5
High
136.7
3
Volumen
649
Märkte
US ETFs
XBI
Vollständige Grafik anzeigen
Full chart
Übersicht
Alle Anlagen
Heatmap
Top-Positionen
Market Value
Shares
Weight %
D
DAWN
Day One Biopharmaceuticals Inc
24.2 M
2.6 M
0.3%
ORIC
ORIC Pharmaceuticals Inc
24.0 M
2.9 M
0.3%
REPL
Replimune Group Inc
22.7 M
2.3 M
0.3%
SPRY
ARS Pharmaceuticals Inc
22.3 M
1.9 M
0.3%
IBRX
ImmunityBio Inc
19.9 M
10.1 M
0.3%
ORKA
Oruka Therapeutics Inc
19.3 M
637.7 K
0.2%
CTMX
CytomX Therapeutics Inc
19.3 M
4.5 M
0.2%
OLMA
Olema Pharmaceuticals Inc
18.6 M
745.8 K
0.2%
RAPT Therapeutics Inc
18.5 M
546.6 K
0.2%
SANA
Sana Biotechnology Inc
18.5 M
4.5 M
0.2%
EBS
Emergent BioSolutions Inc
18.2 M
1.5 M
0.2%
GERN
Geron Corp
18.0 M
13.6 M
0.2%
KALV
KalVista Pharmaceuticals Inc
17.6 M
1.1 M
0.2%
GLUE
Monte Rosa Therapeutics Inc
17.5 M
1.1 M
0.2%
UPB
Upstream Bio Inc
17.4 M
641.1 K
0.2%
SION
Sionna Therapeutics Inc
16.8 M
409.1 K
0.2%
LXEO
Lexeo Therapeutics Inc
16.8 M
1.7 M
0.2%
BCAX
Bicara Therapeutics Inc
16.7 M
991.2 K
0.2%
VSTM
Verastem Inc
16.5 M
2.1 M
0.2%
GOSS
Gossamer Bio Inc
16.1 M
5.2 M
0.2%
1
2
3
4
5
6
7
8
Nachrichten
First Quarter Earnings: Sharpening Sector Divergence
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
3 Reasons To Stick With Growth Stocks In Rotating Markets
Seeking Innovation Beyond Tech? Insight On Healthcare Stocks
Biotech Investors Are Tuning Out the MAHA Chaos
Makary's Successor Faces Tough Task Managing FDA Amid Budget Cuts
Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI)
Capricor: B. Riley bestätigt Kursziel von 63 US-Dollar angesichts von FDA-Fortschritten
FDA Commissioner Marty Makary Expected To Resign, Ending Turbulent Stint
Why I Now Favor A Barbell Model Over Ray Dalio’s All-Weather Portfolio (SPY)
Mizuho senkt Kursziel für Immunocore wegen Umsatzprognose auf 34 Dollar
What's The Dominant Trend In Earnings: AI Or Geopolitics?